AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12203058 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture, group L (1.72 +/- 0.06 g/kg per day)
Number of subjects: 30
Study 10331442 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP205)
Number of subjects: 0
Study 10331442 — intervention group
Group type: EXPERIMENTAL
Intervention: CLTB-36
Number of subjects: 0
Study 8910647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasensitive enzyme immunoassay for simultaneous detection of p24 antigen and antibody IgGs to p17 and reverse transcriptase of HIV-1
Number of subjects: 179
Study 8910647 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods for HIV-1 antibody detection
Number of subjects: 179
Study 8478300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg once daily (od)
Number of subjects: 60
Study 8478300 — intervention group
Group type: COMPARATOR
Intervention: Miocamycin 600 mg twice daily (bd)
Number of subjects: 60
Study 8478300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 60
Study 8478300 — intervention group
Group type: COMPARATOR
Intervention: Miocamycin
Number of subjects: 60
Study 8478300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin and Miocamycin
Number of subjects: 60
Study 3515921 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg BID (twice daily)
Number of subjects: 143
Study 3515921 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg QID (four times daily)
Number of subjects: 143
Study 3515921 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen treatment (both regimens)
Number of subjects: 143
Study 29553418 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg preservative-free morphine
Number of subjects: 121
Study 29553418 — intervention group
Group type: COMPARATOR
Intervention: 20 μg fentanyl
Number of subjects: 121
Study 29058837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (Oxynorm® instant)
Number of subjects: 121
Study 29058837 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (Tradonal® odis)
Number of subjects: 121
Study 24159772 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatotropic drug Vitaprost along with comprehensive treatment including preoperative trophic and flebotonic therapy, laparoscopic surgical clipping of the internal spermatic vein, and post-operative rehabilitation.
Number of subjects: 90
Study 24159772 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive treatment including preoperative trophic and flebotonic therapy, laparoscopic surgical clipping of the internal spermatic vein, and post-operative rehabilitation without Vitaprost.
Number of subjects: 90
Study 21873710 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 10305
Study 21873710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study 21495322 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconat 0.2% for mouthrinsing twice a day
Number of subjects: 49
Study 21495322 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF 0.05% for mouthrinsing twice a day
Number of subjects: 49
Study 21495322 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study 16763073 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple PIL incorporating pictograms
Number of subjects: 0
Study 16763073 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-only PIL
Number of subjects: 0
Study 16763073 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no PIL)
Number of subjects: 0
Study 15037060 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatic and luminance contrast discrimination
Number of subjects: 1
Study 15037060 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoluminant borders discrimination
Number of subjects: 1
Study 15037060 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple displays
Number of subjects: 1
Study 15037060 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex displays
Number of subjects: 1
Study 15037060 — intervention group
Group type: EXPERIMENTAL
Intervention: Local chromatic-contrast
Number of subjects: 1
Study 15037060 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge integration
Number of subjects: 1
Study 11417424 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude (2,000 m) group
Number of subjects: 20
Study 11417424 — intervention group
Group type: COMPARATOR
Intervention: Low altitude (600 m) group
Number of subjects: 20
Study 9686089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil group (0.2 mg.kg‐1 sufentanil added to 0.5% bupivacaine 1 mg.kg‐1 and 1% lidocaine 2 mg.kg‐1)
Number of subjects: 40
Study 9686089 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.5% bupivacaine 1 mg.kg‐1 and 1% lidocaine 2 mg.kg‐1)
Number of subjects: 40
Study 9686089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil group
Number of subjects: 40
Study 8317528 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 459
Study 8317528 — intervention group
Group type: COMPARATOR
Intervention: Intact group
Number of subjects: 459
Study 3758365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection technique combined with radiotherapy
Number of subjects: 0
Study 3758365 — intervention group
Group type: COMPARATOR
Intervention: Sampling technique
Number of subjects: 0
Study 31560101 — intervention group
Group type: COMPARATOR
Intervention: Check Out (CO)
Number of subjects: 167
Study 31560101 — intervention group
Group type: COMPARATOR
Intervention: Email Counselling (EC)
Number of subjects: 167
Study 30502990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVTA)
Number of subjects: 41
Study 30502990 — intervention group
Group type: COMPARATOR
Intervention: Standard vitrectomy and peeling (Control)
Number of subjects: 41
Study 26803522 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (1mg/kg per 12h for five days)
Number of subjects: 48
Study 25540972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic action control group
Number of subjects: 0
Study 25540972 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual action control group
Number of subjects: 0
Study 25540972 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 22634908 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MC - morphine 0.1 mg/ml and clonidine 5 μg/ml continuously infused at 5 ml/h
Number of subjects: 60
Study 22634908 — intervention group
Group type: COMPARATOR
Intervention: Group BM - bupivacaine 0.125% and morphine 0.1 mg/ml
Number of subjects: 60
Study 22634908 — intervention group
Group type: COMPARATOR
Intervention: Group BC - bupivacaine 0.125% and clonidine 5 μg/ml
Number of subjects: 60
Study 22634908 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MC - morphine 0.1 mg/ml and clonidine 5 μg/ml
Number of subjects: 60
Study 20538262 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to multi-modal cues (picture, video, and in-vivo)
Number of subjects: 0
Study 20538262 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer inter-session intervals (4-7 days)
Number of subjects: 0
Study 18640686 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG patients at 5 weeks post-surgery
Number of subjects: 61
Study 18640686 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG patients at 5 months post-surgery
Number of subjects: 61
Study 18640686 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (HS), n = 33
Number of subjects: 61
Study 16400501 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate cement (CPC)
Number of subjects: 136
Study 16400501 — intervention group
Group type: COMPARATOR
Intervention: Iodoform paste
Number of subjects: 136
Study 12590622 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal
Number of subjects: 30
Study 12590622 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study 10230950 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g administered 30 minutes before CPB)
Number of subjects: 52
Study 8628979 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 5000
Study 8628979 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 5000
Study 8628979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study 8628979 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 5000
Study 8628979 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 100 mg slow release
Number of subjects: 5000
Study 8628979 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 750-1000 mg
Number of subjects: 5000
Study 1892794 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenol
Number of subjects: 76
Study 1892794 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain fatty acids
Number of subjects: 76
Study 1892794 — intervention group
Group type: COMPARATOR
Intervention: Control (no pheromone exposure)
Number of subjects: 76
Study 6118170 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine (12 mg)
Number of subjects: 9
Study 6118170 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbinoxamine (12 mg)
Number of subjects: 9
Study 6118170 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (1 mg)
Number of subjects: 9
Study 6118170 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (50 mg)
Number of subjects: 9
Study 6118170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31087200 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) every 2 weeks until disease progression or toxicity requiring study discontinuation
Number of subjects: 493
Study 31087200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 30894299 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain, adaptive, computerized cognitive training for 30 minutes, 5 days/week for 7 weeks
Number of subjects: 60
Study 30894299 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain, adaptive, computerized cognitive training
Number of subjects: 60
Study 30894299 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 60
Study 29096197 — intervention group
Group type: EXPERIMENTAL
Intervention: Real continuous theta-burst (cTBS) to the left-M1 during Feedback (FB) learning condition
Number of subjects: 0
Study 29096197 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous theta-burst (cTBS) to the left-M1 during Feedback (FB) learning condition
Number of subjects: 0
Study 29096197 — intervention group
Group type: EXPERIMENTAL
Intervention: Real continuous theta-burst (cTBS) to the left-M1 during paired associate (PA) learning condition
Number of subjects: 0
Study 29096197 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous theta-burst (cTBS) to the left-M1 during paired associate (PA) learning condition
Number of subjects: 0
Study 26490494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch Healthy Nutrient and Food Score (DHNaFS) - fifth quintile
Number of subjects: 4307
Study 26490494 — intervention group
Group type: COMPARATOR
Intervention: Dutch Undesirable Nutrient and Food Score (DUNaFS)
Number of subjects: 4307
Study 24395612 — intervention group
Group type: COMPARATOR
Intervention: Baseline ALA measurement
Number of subjects: 842
Study 24395612 — intervention group
Group type: COMPARATOR
Intervention: Average of baseline and follow-up ALA measurements
Number of subjects: 842
Study 24395612 — intervention group
Group type: COMPARATOR
Intervention: Baseline total long chain omega-3 FAs (EPA + DHA + DPA) measurement
Number of subjects: 842
Study 24395612 — intervention group
Group type: COMPARATOR
Intervention: Average of baseline and follow-up total long chain omega-3 FAs (EPA + DHA + DPA) measurements
Number of subjects: 842
Study 21658141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 214
Study 21658141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 214
Study 21658141 — intervention group
Group type: COMPARATOR
Intervention: Bupropion and Nortriptyline
Number of subjects: 214
Study 19709993 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Reporting System (SRS)
Number of subjects: 34
Study 19709993 — intervention group
Group type: COMPARATOR
Intervention: Conventional free-text dictation
Number of subjects: 34
Study 17583466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD (200mg or 300mg)
Number of subjects: 1028
Study 17583466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD
Number of subjects: 1028
Study 17583466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1028
Study 15024939 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study 11752122 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of MDMA plus 0.8 g/kg ethanol
Number of subjects: 9
Study 11752122 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of MDMA
Number of subjects: 9
Study 11752122 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg of ethanol
Number of subjects: 9
Study 11752122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9615259 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg om
Number of subjects: 704
Study 9615259 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 10 mg om
Number of subjects: 704
Study 9615259 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg bd
Number of subjects: 704
Study 7652070 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient wound control after 30 days (group I)
Number of subjects: 315
Study 7652070 — intervention group
Group type: COMPARATOR
Intervention: Self-control by questionnaire (group II)
Number of subjects: 315
Study 2649330 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving with self-monitoring of blood glucose (SMBG) integrated into standard outpatient care
Number of subjects: 0
Study 2649330 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 0
Study 882110 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G administered intravenously every four hours for a total of 50,000 U per kilogram per day
Number of subjects: 0
Study 31512830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with alumina particles at 0.2 MPa pressure (groups A, B, C)
Number of subjects: 48
Study 31512830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 120 µm particle size at 0.7 MPa pressure (group D)
Number of subjects: 48
Study 31512830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etching with 98% concentrated sulfuric acid for 60, 120, and 300 s (groups E, F, G)
Number of subjects: 48
Study 31512830 — intervention group
Group type: COMPARATOR
Intervention: Control group H (no surface treatment)
Number of subjects: 48
Study 28003068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block (FICB)
Number of subjects: 46
Study 28003068 — intervention group
Group type: COMPARATOR
Intervention: Local Anesthetic Infiltration (LAI)
Number of subjects: 46
Study 26016146 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy course with a fractional dose of 3 Gy to 42 Gy SOD (SDeq 51 Gy) in group 1 (20 patients)
Number of subjects: 60
Study 26016146 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy using dynamic dose fractionation: fractional doses of 4, 3, and 2 Gy to 51 Gy SDeq in group 2 (20 patients)
Number of subjects: 60
Study 26016146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment using dynamic dose fractionation: fractional doses of 4, 3, and 2 Gy to 56 Gy SDeq and chemotherapy (Xeloda or ftorafur) in group 3 (20 patients)
Number of subjects: 60
Study 23167953 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg vitamin C
Number of subjects: 244
Study 23167953 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C
Number of subjects: 244
Study 21706269 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparanase-1 (HPA-1) expression in malignant cases
Number of subjects: 44
Study 21706269 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor (VEGF) expression in malignant cases
Number of subjects: 44
Study 21706269 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor receptor-2 (VEGFR-2) expression in malignant cases
Number of subjects: 44
Study 21706269 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvessel density (MVD) in malignant cases
Number of subjects: 44
Study 21706269 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of HPA-1 and VEGF with MVD
Number of subjects: 44
Study 18840118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided catheter placement with nerve stimulation assistance (US)
Number of subjects: 100
Study 18840118 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating catheter (ST)
Number of subjects: 100
Study 18840118 — intervention group
Group type: COMPARATOR
Intervention: Traditional nerve stimulation (TR)
Number of subjects: 100
Study 16567439 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue contrast agent administration
Number of subjects: 14
Study 12654143 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural support roll and postural support nappy
Number of subjects: 123
Study 12654143 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural support roll (with or without postural support nappy)
Number of subjects: 123
Study 12654143 — intervention group
Group type: COMPARATOR
Intervention: Postural support roll only
Number of subjects: 123
Study 12654143 — intervention group
Group type: COMPARATOR
Intervention: Postural support nappy only
Number of subjects: 123
Study 10781116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg.kg‐1
Number of subjects: 150
Study 10781116 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.04 mg.kg‐1
Number of subjects: 150
Study 10781116 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 150
Study 8640163 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 alone (Arm 1)
Number of subjects: 30
Study 8640163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential IL-3 -> G-CSF (Arm 2)
Number of subjects: 30
Study 8640163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential IL-3 -> GM-CSF (Arm 3)
Number of subjects: 30
Study 8640163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IL-3 + G-CSF (Arm 4)
Number of subjects: 30
Study 8640163 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF after PBSC infusion
Number of subjects: 30
Study 1451712 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen-codeine 200 mg : 30 mg
Number of subjects: 165
Study 1451712 — intervention group
Group type: COMPARATOR
Intervention: acetylsalicylic acid-codeine 500 mg : 30 mg
Number of subjects: 165
Study 1451712 — intervention group
Group type: COMPARATOR
Intervention: codeine 30 mg
Number of subjects: 165
Study 6693621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionescu-Shiley bovine pericardial xenograft in the mitral position
Number of subjects: 70
Study 31302719 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 31302719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30297397 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1)
Number of subjects: 4549
Study 26358120 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative regular diet of 900 kcal/day (group 1)
Number of subjects: 60
Study 26358120 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative balanced energy high-protein formula (group 2)
Number of subjects: 60
Study 26358120 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Immunonutrition (group 3)
Number of subjects: 60
Study 23884689 — intervention group
Group type: EXPERIMENTAL
Intervention: Items studied aloud
Number of subjects: 0
Study 23884689 — intervention group
Group type: COMPARATOR
Intervention: Items studied silently
Number of subjects: 0
Study 22451451 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80-160 mg per day)
Number of subjects: 150
Study 22451451 — intervention group
Group type: COMPARATOR
Intervention: Non-RAS inhibitor treatment
Number of subjects: 150
Study 19121416 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate 4 mg
Number of subjects: 14
Study 19121416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18214124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo group (ice mapping with catheter tip temperature to -40 degrees C)
Number of subjects: 30
Study 18214124 — intervention group
Group type: COMPARATOR
Intervention: RF group (radiofrequency ablation using standard techniques)
Number of subjects: 30
Study 15025891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenergy awareness training
Number of subjects: 27
Study 11830920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg per day)
Number of subjects: 103
Study 11830920 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus CMF (C 500 mg/m2, M 40 mg/m2, F 600 mg/m2 on days 1st and 8th q 28 day for 6 cycles)
Number of subjects: 103
Study 11830920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 103
Study 11830920 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus CMF
Number of subjects: 103
Study 9552047 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant interferon alfa-2a treatment (3 mIU subcutaneously daily for 3 weeks, then 3 mIU three times per week for 1 year)
Number of subjects: 311
Study 9552047 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 311
Study 7917369 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose carboplatin (30 mg/m2 on days 1-5, weeks 1, 3, 5, and 7)
Number of subjects: 55
Study 7917369 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose carboplatin (up to 55 mg/m2)
Number of subjects: 55
Study 7917369 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose carboplatin and radiotherapy (70 Gy)
Number of subjects: 55
Study 7917369 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose carboplatin and radiotherapy (40-45 mg/m2)
Number of subjects: 55